PWG
ALNY icon

Portside Wealth Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Portside Wealth Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+721
New +$217K 0.03% 473
2026
Q1 		– Sell
-546
Closed -$217K – 467
2025
Q4 		$217K Sell
546
-205
-27% -$90.7K 0.03% 432
2025
Q3 		$342K Buy
+751
New +$306K 0.05% 339

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Portside Wealth Group's ALNY Position: Q2 2026 in Review

Portside Wealth Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 721 shares worth $217K. The stake represents 0.03% of the portfolio and ranks #473 among its holdings. This is a return to the name: Portside Wealth Group previously reported a position in ALNY as recently as Q4 2025.

Portside Wealth Group first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $342K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Portside Wealth Group held 721 shares of Alnylam Pharmaceuticals worth $217K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Portside Wealth Group position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.03% of Portside Wealth Group's portfolio in Q2 2026, its #473 holding.
  • Portside Wealth Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Portside Wealth Group's Alnylam Pharmaceuticals position peaked at $342K in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.